Cytokine-dependent imatinib resistance in mouse BCR-ABL+, Arf-null lymphoblastic leukemia

Genes and Development

Volumn 21, Issue 18, 2007, Pages 2283-2287

  Williams, Richard T ^a   Den Besten, Willem ^a   Sherr, Charles J ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

Arf tumor suppressor; BCR ABL kinase; Cytokines; Drug resistance; Imatinib (Gleevec); Leukemia initiating cells

Indexed keywords

ARF PROTEIN; BCR ABL PROTEIN; CYTOKINE; IMATINIB; RECOMBINANT INTERLEUKIN 7;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW CELL; CELL POPULATION; CELL PROLIFERATION; CELL RENEWAL; CONTROLLED STUDY; DRUG MECHANISM; DRUG TREATMENT FAILURE; HEMATOPOIESIS; LYMPHATIC LEUKEMIA; MAXIMUM TOLERATED DOSE; MOUSE; NONHUMAN; ONCOGENE; POLYCLONAL ACTIVATION; PRE B LYMPHOCYTE; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE;

ANIMALS; ANTINEOPLASTIC AGENTS; CYCLIN-DEPENDENT KINASE INHIBITOR P16; CYTOKINES; DRUG RESISTANCE, NEOPLASM; FUSION PROTEINS, BCR-ABL; HEMATOPOIETIC STEM CELLS; LEUKEMIA, LYMPHOCYTIC, ACUTE; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, SCID; MODELS, BIOLOGICAL; NEOPLASM TRANSPLANTATION; PIPERAZINES; PYRIMIDINES; TREATMENT FAILURE;

MUS;

EID: 34548841964     PISSN: 08909369     EISSN: 15495477     Source Type: Journal    
DOI: 10.1101/gad.1588607     Document Type: Article

References (35)

1. Alvarado, Y., Apostolidou, E., Swords, R., and Giles, F.J. 2007. Emerging therapeutic options for Philadelphia-positive acute lymphocytic leukemia. Expert Opin. Emerg. Drugs 12: 165-179.
2. Borzillo, G.V. and Sherr, C.J. 1989. Early pre-B-cell transformation induced by the v-fms oncogene in long-term mouse bone marrow cultures. Mol. Cell. Biol. 9: 3973-3981.
3. Castor, A., Nilsson, L., Astrand-Grundstrom, I., Buitenhuis, M., Ramirez, C., Anderson, K., Strombeck, B., Garwicz, S., Bekassy, A.N., Schmiegelow, K., et al. 2005. Distinct patterns of hematopoietic stem cell involvement in acute lymphoblastic leukemia. Nat. Med. 11: 630-637.
4. Clarke, M.F., Dick, J.E., Dirks, P.B., Eaves, C.J., Jamieson, C.H.M., Jones, D.L., Visvader, J., Weissman, I.L., and Wahl, G.M. 2006. Cancer stem cells - Perspectives on current status and future directions: AACR workshop on cancer stem cells. Cancer Res. 66: 9339-9344.
5. Clarkson, B., Strife, A., Wisniewski, D., Lambek, C.J., and Liu, C. 2003. Chronic myelogenous leukemia as a paradigm of early cancer and possible curative strategies. Leukemia 17: 1211-1262.
6. de Labarthe, A., Rousselot, P., Huguet-Rigal, F., Delabesse, E., Witz, F., Maury, S., Rea, D., Cayuela, J.-M., Vekemans, M.-C., Reman, O., et al. 2007. Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: Results of the GRAAPH-2003 study. Blood 109: 1408-1413.
7. Dominici, M., Pritchard, C., Garlits, J.E., Hofmann, T.J., Persons, D.A., and Horwitz, E.M. 2004. Hematopoietic cells and osteoblasts are derived from a common marrow progenitor after bone marrow transplantation. Proc. Natl. Acad. Sci. 101: 11761-11766.
8. Druker, B.J., Talpaz, M., Resta, D.J., Peng, B., Buchdunger, E., Ford, J.M., Lydon, N.B., Kantarjian, H., Capdeville, R., Ohno-Jones, S., et al. 2001. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med. 344: 1031-1037.
9. Druker, B.J., Guilhot, F., O'Brien, S.G., Gathmann, I., Kantarjian, H., Gattermann, N., Deininger, M.W., Silver, R.T., Goldman, J.M., Stone, R.M., et al. 2006. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N. Engl. J. Med. 355: 2408-2417.
10. Fialkow, P.J., Denman, A.M., Jacobsen, R.J., and Lowenthal, M.N. 1978. Chronic myelocytic leukemia. Origin of some lymphocytes from leukemic stem cells. J. Clin. Invest. 62: 815-823.
11. Heerema, N.A., Harbott, J., Galimberti, S., Camitta, B.M., Gaynon, P.S., Janka-Schaub, G., Kamps, W., Basso, G., Pui, C.-H., and Schrappe, M. 2004. Secondary cytogenetic aberrations in childhood Philadelphia chromosome positive acute lymphoblastic leukemia are nonrandom and may be associated with outcome. Leukemia 18: 693-702.
12. Hochhaus, A., Kantarjian, H.M., Baccarani, M., Lipton, J.H., Apperley, J.F., Druker, B.J., Facon, T., Goldberg, S.L., Cervantes, F., Niederwieser, D., et al. 2007. Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood 109: 2303-2309.
13. Hu, Y., Liu, Y., Pelletier, S., Buchdunger, E., Warmuth, M., Fabbro, D., Hallek, M., Van Etten, R.A., and Li, S. 2004. Requirement of Src kinases Lyn, Hck, and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia. Nat. Genet. 36: 453-461.
14. + leukemia in mice. Proc. Natl. Acad. Sci. 103: 16870-16875.
15. Jacobs, J.J.L., Kieboom, K., Marino, S., DePinho, R.A., and van Lohuizen, M. 1999. The oncogene and Polycomb-group gene bmi-1 regulates cell proliferation and senescence through the ink4a locus. Nature 397: 164-168.
16. ARF. Cell 91: 649-659.
17. Kantarjian, H., Giles, F., Wunderle, L., Bhalla, K., O'Brien, S., Wassmann, B., Tanaka, C., Manley, P., Rae, P., Mietlowski, W., et al. 2006. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N. Engl. J. Med. 354: 2542-2551.
18. Kim, W.Y. and Sharpless, N.E. 2006. The regulation of INK4/ARF in cancer and aging. Cell 127: 265-275.
19. McLaughlin, J., Chianese, E., and Witte, O.N. 1987. In vitro transformation of immature hematopoietic cells by the P210 BCR/ABL oncogene product of the Philadelphia chromosome. Proc. Natl. Acad. Sci. 84: 6558-6562.
20. Mullighan, C.G., Goorha, S., Radtke, I., Miller, C.B., Coustan-Smith, E., Dalton, J.D., Girtman, K., Mathew, S., Ma, J., Pounds, S.B., et al. 2007. Genome-wide analysis of genetic alterations in acute lymphoblastic leukemia. Nature 446: 758-764.
21. O'Hare, T., Eide, C.A., and Deininger, M.W. 2007. Bcr-Abl kinase domain mutations, drug resistance and the road to a cure of chronic myeloid leukemia. Blood doi: 10.1182/blood-2007-03-066936.
22. Park, I.-K., Qian, D., Kiel, M., Becker, M.W., Pihalja, M., Weissman, I.L., Morrison, S.J., and Clarke, M.F. 2003. Bmi-1 is required for maintenance of adult self-renewing haematopoietic stem cells. Nature 423: 302-305.
23. + adult B-cell precursor acute lymphoblastic leukemia: Impact on the clinical, biological, and immunophenotypical disease characteristics. Leukemia 19: 713-720.
24. Ink4a loss on senescence of murine bone marrow-derived pre-B cells and macrophages. Proc. Natl. Acad. Sci. 98: 9654-9659.
25. Shah, N.P., Nicoll, J.M., Nagar, B., Gorre, M.E., Paquette, R.L., Kuriyan, J., and Sawyers, C.L. 2002. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2: 117-125.
26. Sherr, C.J. 2006. Divorcing ARF and p53: An unsettled case. Nat. Rev. Cancer 6: 663-673.
27. Shou, Y., Ma, Z., Lu, T., and Sorrentino, B.P. 2006. Unique risk factors for insertional mutagenesis in a mouse model of XSCID gene therapy. Proc. Natl. Acad. Sci. 103: 11730-11735.
28. Talpaz, M., Shah, N.P., Kantarjian, H., Donato, N., Nicoll, J., Paquette, R., Cortes, J., O'Brien, S., Nicaise, C., Bleickardt, E., et al. 2006. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N. Engl. J. Med. 354: 2531-2541.
29. Whitlock, C.A. and Witte, O.N. 1987. Long-term culture of murine bone marrow precursors of B lymphocytes. Methods Enzymol. 150: 275-286.
30. Williams, R.T., Roussel, M.F., and Sherr, C.J. 2006. Arf gene loss enhances oncogenicity and limits imatinib response in mouse models of Bcr-Abl-induced acute lymphoblastic leukemia. Proc. Natl. Acad. Sci. 103: 6688-6693.
31. Wolff, N.C. and Ilaria, R.L. 2001. Establishment of a murine model for therapy-related chronic myelogenous leukemia using the tyrosine kinase inhibitor STI571. Blood 98: 2808-2816.
32. Wolff, N.C., Richardson, J.A., Egorin, M., and Ilaria Jr., R.L. 2003. The CNS is a sanctuary for leukemic cells in mice receiving imatinib mesylate for Bcr/Abl-induced leukemia. Blood 101: 5010-5013.
33. Wolff, N.C., Randle, D.E., Egorin, M.J., Minna, J.D., and Ilaria Jr., R.L. 2004. Imatinib mesylate efficiently achieves therapeutic intratumor concentrations in vivo but has limited activity in a xenograft model of small cell lung cancer. Clin. Cancer Res. 10: 3528-3534.
34. Wong, S. and Witte, O.N. 2004. The BCR-ABL story: Bench to bedside and back. Annu. Rev. Immunol. 22: 247-306.
35. Zindy, F., Eischen, C.M., Randle, D.H., Kamijo, T., Cleveland, J.L., Sherr, C.J., and Roussel, M.F. 1998. Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization. Genes & Dev. 12: 2424-2433.